p62 as a therapeutic target for inhibition of autophagy in prostate cancer

Conclusionsp62 has a high potential to be developed as a therapeutic target. Verteporfin represents a prototypical agent with therapeutic potential against prostate cancer through inhibition of autophagy by a novel mechanism of p62 inhibition.
Source: The Prostate - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research